22 May 2013
Keywords: patients, enter, pivotal, study, genmab, cll, drug
Article | 10 December 2007
Danish drugmaker Genmab AS has completed recruitment in a pivotal study of ofatumumab (HuMax-CD20) for the treatment of refractory chronic
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 December 2007
21 May 2013
© 2013 thepharmaletter.com